PortalPublikationenOverall survival of relapsed and refractory multiple myeloma...

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Standard

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. / Morgan, Gareth; Palumbo, Antonio; Dhanasiri, Sujith; Lee, Dawn; Weisel, Katja; Facon, Thierry; Delforge, Michel; Oriol, Albert; Zaki, Mohamed; Yu, Xin; Sternas, Lars; Jacques, Christian; Akehurst, Ron; Offner, Fritz; Dimopoulos, Meletios A.

in: BRIT J HAEMATOL, Jahrgang 168, Nr. 6, 03.2015, S. 820-3.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Morgan, G, Palumbo, A, Dhanasiri, S, Lee, D, Weisel, K, Facon, T, Delforge, M, Oriol, A, Zaki, M, Yu, X, Sternas, L, Jacques, C, Akehurst, R, Offner, F & Dimopoulos, MA 2015, 'Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone', BRIT J HAEMATOL, Jg. 168, Nr. 6, S. 820-3. https://doi.org/10.1111/bjh.13227

APA

Morgan, G., Palumbo, A., Dhanasiri, S., Lee, D., Weisel, K., Facon, T., Delforge, M., Oriol, A., Zaki, M., Yu, X., Sternas, L., Jacques, C., Akehurst, R., Offner, F., & Dimopoulos, M. A. (2015). Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. BRIT J HAEMATOL, 168(6), 820-3. https://doi.org/10.1111/bjh.13227

Vancouver

Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T et al. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. BRIT J HAEMATOL. 2015 Mär;168(6):820-3. https://doi.org/10.1111/bjh.13227

Bibtex

@article{410e13fe1d5949ca9bb527977c1619e7,
title = "Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone",
abstract = "In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 7·0 months (12·7 vs. 5·7 months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients. ",
keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols, Bias, Cross-Over Studies, Dexamethasone, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Male, Multiple Myeloma, Recurrence, Retrospective Studies, Salvage Therapy, Thalidomide, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "Gareth Morgan and Antonio Palumbo and Sujith Dhanasiri and Dawn Lee and Katja Weisel and Thierry Facon and Michel Delforge and Albert Oriol and Mohamed Zaki and Xin Yu and Lars Sternas and Christian Jacques and Ron Akehurst and Fritz Offner and Dimopoulos, {Meletios A}",
note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",
year = "2015",
month = mar,
doi = "10.1111/bjh.13227",
language = "English",
volume = "168",
pages = "820--3",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

AU - Morgan, Gareth

AU - Palumbo, Antonio

AU - Dhanasiri, Sujith

AU - Lee, Dawn

AU - Weisel, Katja

AU - Facon, Thierry

AU - Delforge, Michel

AU - Oriol, Albert

AU - Zaki, Mohamed

AU - Yu, Xin

AU - Sternas, Lars

AU - Jacques, Christian

AU - Akehurst, Ron

AU - Offner, Fritz

AU - Dimopoulos, Meletios A

N1 - © 2014 John Wiley & Sons Ltd.

PY - 2015/3

Y1 - 2015/3

N2 - In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 7·0 months (12·7 vs. 5·7 months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.

AB - In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 7·0 months (12·7 vs. 5·7 months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bias

KW - Cross-Over Studies

KW - Dexamethasone

KW - Dose-Response Relationship, Drug

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Multiple Myeloma

KW - Recurrence

KW - Retrospective Studies

KW - Salvage Therapy

KW - Thalidomide

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/bjh.13227

DO - 10.1111/bjh.13227

M3 - SCORING: Journal article

C2 - 25403264

VL - 168

SP - 820

EP - 823

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 6

ER -